In our previous studies, we have proposed as a combined treatment strategy that spliceosome inhibition sensitizes B cell lines and CLL primary patient samples to non-genotoxic MDM2-p53 binding antagonists [42] which have previously been shown to be a promising single treatment option for CLL [13]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.